Disc Medicine (IRON) has announced positive additional data regarding bitopertin for the treatment of erythropoietic protoporphyria. Supplemental analyses of the AURORA data further confirm the clinical efficacy of bitopertin, highlighting significant improvements in light tolerance, phototoxic reactions, and overall quality of life for patients. Additionally, the company provided an update on their study of DISC-0974 for anemia associated with myelofibrosis, which continues to exhibit encouraging hematologic activity.
Furthermore, data from the third program, DISC-3405, involving healthy volunteers, indicated clinical proof-of-mechanism as an iron restriction agent, showcasing its potential for a unique profile in this therapeutic area.
For more health news, visit rttnews.com.
